Narval
A new generation of antibody drugs using synthetic antibody mimetic proteins delivered through mucosal and skin tissues
Knoxville, United States
8 employees
Non Equity Assistance
Biotechnology, Health and Wellness +2
General Information
Get notified when Narval moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Discover More
United States Market
Biotechnology
About Narval
Taxonomy: Biopharmaceuticals, Immunotherapeutics, Antibody Engineering, Antibody drugs, Disease treatment, Respiratory diseases, Eye diseases, Autoimmune diseases, Skin diseases, Mucosal delivery, Skin delivery, Antibody mimetic proteins, Immunotherapy, Life Sciences
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | •••••• | 1 |
|
26 Jul 2023 |
Narval Alternatives & Competitors
We are the only UK charity that raises money to fund research into all types of skin diseases, inclu...
Offering advanced micro-needling treatments for wrinkle reduction and scar healing, alongside specia...
Antibody discovery, antibody engineering.
FAQ About Narval
Don't just browse. Track.
Signal Tracker monitors Narval and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
